Michael P Gustafson

List of Publications by Year
in descending order

84	2,695	236833	206029
papers	citations	25 h-index	48 g-index

85	85	85	4988
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience. Cytotherapy, 2022, 24, 16-18.	0.3	1
2	ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products. Cytotherapy, 2022, 24, 27-31.	0.3	5
3	Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.4	6
4	Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. Clinical and Translational Immunology, 2021, 10, e1267.	1.7	4
5	Aggressive Thyroid Cancer is Associated With Suppressor Circulating Immunophenotype. Journal of the Endocrine Society, 2021, 5, A855-A856.	0.1	0
6	Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. , 2021, 9, e001872.		49
7	Acute Exercise Enhances The Ex Vivo Expansion And Cytolytic Phenotype Of Cytokine Induced Killer Cells. Medicine and Science in Sports and Exercise, 2021, 53, 366-366.	0.2	0
8	Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa105.	0.4	8
9	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nature Communications, 2020, 11, 5173.	5.8	46
10	Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. Thyroid, 2020, 30, 1440-1450.	2.4	53
11	The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. Neuro-Oncology, 2020, 22, 967-978.	0.6	62
12	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clinical Cancer Research, 2020, 26, 1045-1053.	3.2	13
13	Phenotypic, Transcriptional, and Functional Analysis of Liver Mesenchymal Stromal Cells and Their Immunomodulatory Properties. Liver Transplantation, 2020, 26, 549-563.	1.3	9
14	The power of immune profiling: quantitative flow cytometry and informatics approaches to generate pooled biomarkers for therapeutic responsiveness to immune and cellular therapies. Cytotherapy, 2020, 22, S118-S119.	0.3	0
15	The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 1147.	2.2	105
16	ATIM-29. IDENTIFYING IMMUNOLOGICAL BARRIERS TO IMMUNOTHERAPY IN PATIENTS WITH GLIOBLASTOMA MULTIFORME. Neuro-Oncology, 2019, 21, vi7-vi8.	0.6	0
17	IMMU-36. THE ROLE OF PD-L1 IN GLIOBLASTOMA-DERIVED EXTRACELLULAR VESICLES IN THE INDUCTION OF IMMUNOSUPPRESSIVE MONOCYTES. Neuro-Oncology, 2019, 21, vi126-vi127.	0.6	0
18	Donor-specific hypo-responsiveness occurs in simultaneous liver-kidney transplant recipients after the first year. Kidney International, 2018, 93, 1465-1474.	2.6	41

#	Article	IF	Citations
19	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clinical Cancer Research, 2018, 24, 3014-3025.	3.2	64
20	Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans. Journal of Visualized Experiments, 2018, , .	0.2	2
21	Sa1480 - Understanding the Immunological Profiles of Somaliamericans with Viral Hepatitis. Gastroenterology, 2018, 154, S-1126-S-1127.	0.6	0
22	Tu1261 - Mesenchymal Stem Cells Instigate Creeping Fat Development via Aberrant Immunomodulatory Functions. Gastroenterology, 2018, 154, S-918.	0.6	0
23	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2770-2780.	1.8	210
24	Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer. Advances in Radiation Oncology, 2017, 2, 540-547.	0.6	27
25	A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood. , 2017, 5, 30.		64
26	Immunosuppressive CD14⁺HLA-DR^{lo/neg}monocytes are elevated in pancreatic cancer and â€œprimedâ€•by tumor-derived exosomes. OncoImmunology, 2017, 6, e1252013.	2.1	59
27	Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS ONE, 2017, 12, e0182002.	1.1	65
28	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Letters, 2016, 380, 163-173.	3.2	72
29	Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Research and Therapy, 2016, 7, 107.	2.4	130
30	ATIM-31. ALLOGENEIC TUMOR LYSATE / AUTOLOGOUS DENDRITIC CELL VACCINES IN NEWLY DIAGNOSED GLIOBLASTOMA: CLINICAL TRIAL MC1272. Neuro-Oncology, 2016, 18, vi24-vi25.	0.6	2
31	Novel cell surface markers reveal biological variability in adipose-derived mesenchymal stromal cell (AMSC) expansion: applications for regenerative cell therapy. Cytotherapy, 2015, 17, S33.	0.3	0
32	Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+â€‰HLA-DRlo/neg) found in aggressive pediatric sarcoma patients. , 2015, 3, 35.		45
33	Using whole immune system characterization (immune profiling) to identify immune biomarkers to determine patient selection, dosing, and efficacy of new immune therapies. , 2015, 3, .		0
34	A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans. PLoS ONE, 2015, 10, e0121546.	1.1	100
35	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 4224-4233.	3.2	33
36	Manufacture of monocyte-derived dendritic cells to stimulate anti-tumor immunity in Phase I trials: the mayo clinic experience. Cytotherapy, 2015, 17, S18-S19.	0.3	0

#	Article	IF	Citations
37	Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: clinical trial in progress. Cytotherapy, 2015, 17, S17.	0.3	1
38	Using comprehensive immune profiles to identify glioblastoma patients responsive to autologous dendritic cell vaccines. Cytotherapy, 2015, 17, S17.	0.3	0
39	IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/â^' monocytes in B-cell non-Hodgkin lymphoma. Blood Cancer Journal, 2015, 5, e328-e328.	2.8	79
40	IT-24 * DEVELOPMENT OF A NOVEL AUTOLOGOUS DENDRITIC CELL / ALLOGENEIC GLIOBLASTOMA LYSATE VACCINE PROTOCOL. Neuro-Oncology, 2014, 16, v114-v115.	0.6	0
41	Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity. Cancer Immunology Research, 2014, 2, 241-248.	1.6	29
42	Immune Profiling to Predict Treatment Response from Extracorporeal Photopheresis in Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, S263.	2.0	0
43	Discordant CD34+ cell results in peripheral blood and hematopoietic progenitor cell-apheresis product: implications for clinical decisions and impact on patient treatment. Transfusion, 2014, 54, 541-544.	0.8	4
44	Strategies for improving the reporting of human immunophenotypes by flow cytometry. , 2014, 2, 18.		11
45	Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response. , 2014, 2, 4.		38
46	Classifying patients and monitoring the outcomes of cell based therapies using immunomics. Cytotherapy, 2014, 16, S15-S16.	0.3	0
47	Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses. Frontiers in Immunology, 2014, 5, 147.	2.2	55
48	A method for non-overlapping identification of human myeloid derived suppressor cells. , 2014, 2, .		1
49	Lymphoma monocyte crosstalk via HSP27 to promote immune suppression and chemotherapy resistance. , 2014, 2, P222.		0
50	Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress. , 2014, 2, .		0
51	Rethinking cancer immunotherapy: Using advanced cancer genetics in immuneâ€mediated eradication of gastrointestinal cancers. Hepatology, 2014, 60, 2121-2124.	3.6	4
52	Dendritic Cell Vaccine Treatment for B-Cell Non-Hodgkin Lymphoma: Clinical Trial in Progress. Blood, 2014, 124, 4474-4474.	0.6	3
53	Presence and function of CD14+CD16-HLADRlow monocytes in the peripheral blood of patients with Î'-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2014, 32, e19539-e19539.	0.8	0
54	Lymphoma Monocyte Crosstalk Via Hsp27 to Promote Immune Suppression and Chemotherapy Resistance. Blood, 2014, 124, 2966-2966.	0.6	0

#	Article	IF	Citations
55	IL-10 Contributes to the Development of Immunosuppressive CD14+HLA-DRlow/- monocytes in B-Cell Non-Hodgkinâ€™s Lymphoma. Blood, 2014, 124, 2979-2979.	0.6	0
56	Immune monitoring using the predictive power of immune profiles. , 2013, 1, 7.		50
57	Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma. Cancer Research, 2013, 73, 897-907.	0.4	161
58	Immune monitoring using the predictive power of immune profiles. Cytotherapy, 2013, 15, S48.	0.3	1
59	The CD4+/CD14+HLA-DRlo/neg ratio as a prognostic biomarker in cancer patients. , 2013, 1, .		0
60	Ten-color, whole blood flow cytometric analysis of human myeloid subsets; implications for immune monitoring in cancer patients. , 2013, 1, .		0
61	Expression profiling of suppressive monocytes (CD14+HLA-DRlow/neg) in cancer patients. , 2013, 1, .		0
62	Tumor monocyte cross talk promotes lymphoma cell resistance to chemotherapy. , 2013, 1, P179.		0
63	Association of an increased frequency of CD14⁺HLAâ€DR^{lo/neg} monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). British Journal of Haematology, 2012, 156, 674-676.	1.2	58
64	Abstract 4905: The BH3 mimetic navitoclax (ABT-263) selectively induces apoptosis in cholangiocarcinoma-associated fibroblasts thereby reducing tumor growth. , 2012, , .		0
65	Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells.. Journal of Clinical Oncology, 2012, 30, 2546-2546.	0.8	0
66	Immunosuppressive CD14+HLA-DRlow/â^' monocytes in B-cell non-Hodgkin lymphoma. Blood, 2011, 117, 872-881.	0.6	218
67	Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro-Oncology, 2010, 12, 631-644.	0.6	194
68	Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks. Clinical Cancer Research, 2010, 16, 5573-5580.	3.2	68
69	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology, 2010, 12, 351-365.	0.6	197
70	Abstract 5303: Systemic immunosuppression in glioblastoma: the interplay between lymphopenia, CD14+HLA-DRlo/negmonocytes, tumor factors, and dexamethasone. , 2010, , .		0
71	Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D.. Journal of Clinical Oncology, 2010, 28, 2016-2016.	0.8	1
72	Immune Phenotyping and Naive T Cells as a Predictor of Response to Therapy In Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 1362-1362.	0.6	0

#	Article	IF	Citations
73	Increased Immune Suppressive CD14+ hla-DRneg Circulating Monocytes Are Found in Aggressive Non-Hodgkin's Lymphoma and Correlated with Increased Arginase I Level.. Blood, 2009, 114, 970-970.	0.6	0
74	Isoform- and cell cycleâ€“dependent substrate degradation by the Fbw7 ubiquitin ligase. Journal of Cell Biology, 2008, 181, 913-920.	2.3	105
75	Therapeutic vaccines for malignant brain tumors. Biologics: Targets and Therapy, 2008, 2, 753.	3.0	8
76	A Population of Suppressive Monocytes Inhibiting T Cell Proliferation and Dendritic Cell Differentiation in Relapsed Non-Hodgkinâ€™s Lymphoma. Blood, 2008, 112, 808-808.	0.6	0
77	Regulation of cell proliferation in a stratified culture system of epithelial cells from prostate tissue. Cell and Tissue Research, 2006, 325, 263-276.	1.5	7
78	Zcchc8 is a glycogen synthase kinase-3 substrate that interacts with RNA-binding proteins. Biochemical and Biophysical Research Communications, 2005, 338, 1359-1367.	1.0	23
79	Differential Regulation of Growth and Checkpoint Control Mediated by a Cdc25 Mitotic Phosphatase from Pneumocystis carinii. Journal of Biological Chemistry, 2001, 276, 835-843.	1.6	26
80	Pneumocystis cariniiContains a Functional Cell-division-cycle Cdc2 Homologue. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 297-306.	1.4	51
81	Characterization of the Pneumocystis carinii Cyclin-Dependent Kinase Life Cycle Regulatory System. Journal of Eukaryotic Microbiology, 1997, 44, 32s-32s.	0.8	3
82	Identification of a Cell Division Cycle (cdc2) Homologue in Pneumocystis carinii. Journal of Eukaryotic Microbiology, 1996, 43, 11S-11S.	0.8	8
83	Pneumocystis carinii Modulates Cyclin-Dependant Kinase Activity in a Lung Epithelial Cell Line. Journal of Eukaryotic Microbiology, 1996, 43, 13S-13S.	0.8	5
84	Neuroendocrine profile of the potential anxiolytic drug S-20499. European Journal of Pharmacology, 1995, 274, 141-149.	1.7	11